CN1894211A - 借助费歇尔－芬克型合成和随后的酰化制备4,5－二烷基－3－酰基－吡咯－2－羧酸衍生物 - Google Patents

借助费歇尔－芬克型合成和随后的酰化制备4,5－二烷基－3－酰基－吡咯－2－羧酸衍生物 Download PDF

Info

Publication number
CN1894211A
CN1894211A CNA2004800377619A CN200480037761A CN1894211A CN 1894211 A CN1894211 A CN 1894211A CN A2004800377619 A CNA2004800377619 A CN A2004800377619A CN 200480037761 A CN200480037761 A CN 200480037761A CN 1894211 A CN1894211 A CN 1894211A
Authority
CN
China
Prior art keywords
compound
formula
alkyl
aliphatic group
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800377619A
Other languages
English (en)
Chinese (zh)
Inventor
M·沃雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN1894211A publication Critical patent/CN1894211A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800377619A 2003-10-28 2004-10-28 借助费歇尔－芬克型合成和随后的酰化制备4,5－二烷基－3－酰基－吡咯－2－羧酸衍生物 Pending CN1894211A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51528303P 2003-10-28 2003-10-28
US60/515,283 2003-10-28

Publications (1)

Publication Number Publication Date
CN1894211A true CN1894211A (zh) 2007-01-10

Family

ID=34549387

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800377619A Pending CN1894211A (zh) 2003-10-28 2004-10-28 借助费歇尔－芬克型合成和随后的酰化制备4,5－二烷基－3－酰基－吡咯－2－羧酸衍生物

Country Status (11)

Country Link
US (2) US7250520B2 (https=)
EP (1) EP1678134B1 (https=)
JP (2) JP4942485B2 (https=)
KR (1) KR20060122872A (https=)
CN (1) CN1894211A (https=)
AT (1) ATE442355T1 (https=)
AU (1) AU2004285972A1 (https=)
DE (1) DE602004023105D1 (https=)
ES (1) ES2330944T3 (https=)
IL (1) IL175253A0 (https=)
WO (1) WO2005042484A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
AU2007217355B2 (en) 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
WO2008106058A2 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
HRP20120330T1 (hr) 2007-02-27 2012-05-31 Vertex Pharmaceuticals Incorporated Sukristali i farmaceutski pripravci koji ih sadrže
NZ583699A (en) 2007-08-30 2012-04-27 Vertex Pharma Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
EP2489346A1 (en) 2011-01-26 2012-08-22 NanotecMARIN GmbH Food supplement and injectable material for prophylaxis and therapy of osteoporosis and other bone diseases
JP2015053226A (ja) 2013-09-09 2015-03-19 タイコエレクトロニクスジャパン合同会社 電気コネクタの端子、及び電気コネクタ
US10207974B1 (en) 2017-12-05 2019-02-19 Chevron Phillips Chemical Company Lp Synthesis of gamma dicarbonyl and pyrrole compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223602B8 (en) * 2002-04-11 2010-05-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease
WO2004092161A1 (en) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Also Published As

Publication number Publication date
DE602004023105D1 (de) 2009-10-22
AU2004285972A1 (en) 2005-05-12
US20050143585A1 (en) 2005-06-30
JP2007509991A (ja) 2007-04-19
ES2330944T3 (es) 2009-12-17
JP4942485B2 (ja) 2012-05-30
HK1092134A1 (en) 2007-02-02
WO2005042484A1 (en) 2005-05-12
US20080167480A1 (en) 2008-07-10
KR20060122872A (ko) 2006-11-30
IL175253A0 (en) 2006-09-05
EP1678134B1 (en) 2009-09-09
ATE442355T1 (de) 2009-09-15
JP2011231117A (ja) 2011-11-17
EP1678134A1 (en) 2006-07-12
US7250520B2 (en) 2007-07-31

Similar Documents

Publication Publication Date Title
CN1154493C (zh) 含氮杂环羧酰胺衍生物或其盐以及含有二者的抗病毒药
CN1148503A (zh) 新的肽类化合物在制备药物中的应用
CN1894211A (zh) 借助费歇尔－芬克型合成和随后的酰化制备4,5－二烷基－3－酰基－吡咯－2－羧酸衍生物
CN1076928A (zh) 1-[2-芳磺酰基氨基)-1-氧代乙基]哌啶衍生物及其制备和在治疗上的应用
CN1031842A (zh) 新二唑
CN87103504A (zh) 杂环羧酰胺
CN1122036C (zh) 用于制备奥氮平的中间体和方法
CN1039323C (zh) 咪唑并吡啶衍生物的制备方法
CN1027368C (zh) 新型取代的喹啉衍生物的制备方法
CN1108657A (zh) 雪花胺衍生物、其制备方法及其作为药物的用途
CN1025676C (zh) 非肽的血管紧张肽原酶抑制剂的制备
CN1074904A (zh) 苯并呋喃基-和噻吩基甲硫基-链烷羧酸衍生物
CN1821217A (zh) 反式－4－氨基－1－环己烷羧酸衍生物的制备方法
CN1103534A (zh) 具有抗精神病作用的化合物
CN1027268C (zh) 新颖苯并吡喃酮-β-D-硫代木糖苷的制备方法
CN1205704A (zh) 2,7－取代的八氢－吡咯并[1,2－a]吡嗪衍生物
CN1756753A (zh) 苯并呋喃衍生物
CN1079745A (zh) 新的9-氟-7-氧代-7H-吡啶并[1，2，3-d，e][1，4]苯并嗪-6-羧酸及其酯
CN88101674A (zh) 色酮衍生物
CN100347173C (zh) 具有免疫调制活性的吡唑并喹啉
CN1024790C (zh) 尿素衍生物及其盐的制备方法
CN1155570C (zh) 新的氰基-吲哚5-羟色胺再摄取抑制剂化合物、其制备方法和含有它们的药物组合物
CN1174994C (zh) 胆汁酸衍生物的制备方法
CN1027263C (zh) 吡啶并嘧啶衍生物的制备方法
CN1246298C (zh) 制备酮亚胺的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070110